Dupilumab improves clinical outcome assessments in children with eosinophilic esophagitis in a randomized phase 3 study.

What was studied

This study looked at children aged 1 to 11 years with active EoE. EoE is a long-lasting disease of the food pipe. It was a later look at data from a phase 3 trial. By chance, children got dupilumab or a dummy drug for 16 weeks. In all, 37 children got a higher dose of dupilumab, and 34 got the dummy. Doctors, parents and children filled in forms on signs, symptoms and daily life.

What they found

Parents kept track of days with at least one sign of EoE. These days dropped more with dupilumab than with the dummy drug. But the trial was not built to show if this gap was real. Other scores from parents and doctors also mostly leaned toward dupilumab. Signs seen by parents and symptoms told by children agreed closely.

What it means for patients

The authors saw gains with dupilumab in most doctor and parent scores. In some scores the children gave themselves, the gains were not steady. Parents and children also gave much the same picture of EoE signs.

Why it is not certain yet

The trial was not built to find clear gaps in the main symptom score. This was a later look at the data, not the trial's main aim. The groups held 37 and 34 children. The results cover just 16 weeks of treatment. Some scores from the children did not agree with the other results.

Source

Dupilumab improves clinical outcome assessments in children with eosinophilic esophagitis in a randomized phase 3 study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.